Molecular Partners (OTCMKTS:MLLCF) Trading 90.2% Higher – Should You Buy?

Molecular Partners AG (OTCMKTS:MLLCF)’s share price was up 90.2% on Thursday . The company traded as high as $4.85 and last traded at $4.85. Approximately 150 shares traded hands during trading, a decline of 82% from the average daily volume of 831 shares. The stock had previously closed at $2.55.

Molecular Partners Trading Up 90.2%

The stock’s 50-day moving average is $2.58 and its two-hundred day moving average is $2.91.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.

Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.